# Research Pulse — 2026-09-22 _Generated 2026-09-22 07:34 KST · AI × Bioresearch Daily synthesis_ Brown Biotech daily research pulse — multi-front synthesis across CRISPR / gene editing, AI drug discovery, protein AI, single-cell foundation models, FDA/regulatory, and spatial transcriptomics. Sources: company filings, peer-reviewed journals, FDA guidance, conference disclosures. --- ### Post 1: 오늘의 전체 흐름 🧬 **AI × Bioresearch Daily — 9월 22일 (화요일) · Consolidating(집적화) Day** 9/22(집적화) → 9/21(정상화) → 9/20(실체화) → 9/19(제도화) → 9/18(산업화) → 9/17(확산) → 9/16(종합) → 9/15(검증). Normalizing(9/21)된 기술들이 **성능 수치의 정밀한 집적화·실패 패턴의 체계적 분석·복합 지표의 융합으로 다음 단계 기술적 기반을 강화하는 Consolidating(집적화) 단계로 이전하며, 기술이 반복적 성과 축적과 한계 분석을 통해 실전 적용의 확실성을 높여 가는 날** — Zhao et al.으로 DNA/RNA editingtherapeutic status comprehensive review — in vivo delivery bottleneck 5가지 핵심 제약 체계적 분석 + 1,700건 preclinical evidence 통합(Molecular Biomedicine 2026), Yin et al.으로 ESMFold/RoseTTAFold/AlphaFold3 comprehensive review — drug discovery·enzyme engineering applications + AlphaFold2 88%/77% vs ESMFold 76%/41% 수치确认(Frontiers Molecular Biosciences 2026), Wen et al.으로 spatial transcriptomics cancer research comprehensive review — tumorigenesis·diagnosis·therapeutics 통합 체계화(Cell Death Discovery 2026), Cervilla et al.으로 spatial transcriptomics 5개 플랫폼 기술 비교 — Visium/Xenium/CosMx FFPE tumor same-sample benchmarking + RNA-protein decoupling 발견(Genome Biology 2026)이 동시에 진행된다. Consolidating은 Normalizing의 다음 단계다. 오늘 6개 전선은 정상화된 기술들이 **구체적 수치의 정밀한 집적화·한계의 체계적 분석·복합 지표의 융합으로 기술적 확실성을 강화하며, 이전 단계에서 확인된 성과들을 실전 적용 가능한 수준으로 압축하는 날**이다. *출처: [Zhao DNA RNA Editing Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/), [Yin AlphaFold Comprehensive Frontiers Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/), [Wen Spatial Transcriptomics Cancer Cell Death Discovery 2026](https://consensus.app/papers/details/c7d9a4c29e4253c5b8ee0b203b998107/), [Cervilla Spatial Platforms Genome Biology 2026](https://consensus.app/papers/details/cf934161d7415209a856d6484f37f754/)* *#ConsolidatingDay #Zhao #MolecularBiomedicine #DNAEditing #RNAEditing #InVivoDelivery #Bottleneck #Yin #FrontiersMolecularBiosciences #AlphaFold #ESMFold #RoseTTAFold #ComprehensiveReview #Wen #CellDeathDiscovery #SpatialTranscriptomics #Tumorigenesis #Diagnosis #Therapeutics #Cervilla #GenomeBiology #SpatialPlatforms #FFPE #Xenium #Visium #CosMx #RNAProteinDecoupling #Consolidating #Precision #Integration #BiomedicalAI #DailyReport* --- ### Post 2: CRISPR & Gene Editing — In Vivo Delivery Bottleneck 5가지 체계적 분석과 Preclinical Evidence 1,700건 집적화 🪄 **[CRISPR/Gene Editing] Zhao et al.으로 DNA and RNA editing for human diseases comprehensive review — in vivo delivery bottleneck 5가지 핵심 제약(delivery efficiency·tissue specificity·genotoxicity·immunogenicity·manufacturing complexity) 체계적 분석 + 1,700건 preclinical evidence 통합 + permanent vs reversible editing strategies 비교(Molecular Biomedicine 2026) + Yin et al.으로 ESMFold/RoseTTAFold/AlphaFold3 comprehensive review — drug discovery·enzyme engineering applications + conformational changes/disorder 한계 분석(Frontiers Molecular Biosciences 2026): CRISPR Consolidating(집적화) 동시 확인** CRISPR 유전자 편집 기술의**in vivo delivery bottleneck 5가지 체계적 분석과 1,700건 evidence 집적화(Consolidating)**가 출처에서 동시에 확인된다[1][2]. **DNA/RNA Editing Therapeutic Status: 5가지 In Vivo Delivery Bottleneck 체계적 분석[1]** R. Zhao et al.(Molecular Biomedicine 2026)의 review는 DNA/RNA editing technologies의 치료적 적용 현황과 도전을 종합한다[1]. **핵심 성과 1 — 1,700건 preclinical evidence 통합**: DNA/RNA editing의 현재 증거 기반 집적화. **핵심 성과 2 — In vivo delivery 5가지 bottleneck 체계적 분류**: (i) delivery efficiency, (ii) tissue specificity, (iii) genotoxicity, (iv) immunogenicity, (v) manufacturing complexity. **핵심 성과 3 — Permanent vs reversible editing strategies 비교**: permanent(CRISPR/Cas) vs reversible(RNA editing) 선택 기준. **핵심 성과 4 — Permanent editing + reversible editing 병행 전략**: high cargo-writing capacity + low integration risk. **핵심 성과 5 — Programmable delivery systems**: hard-to-transfect tissues와 complex diseases 적용 가능성. **핵심**: In vivo delivery bottleneck 5가지 체계적 분석 — CRISPR Consolidating Consolidating. **AlphaFold/ESMFold/RoseTTAFold Comprehensive Review: Drug Discovery·Enzyme Engineering Applications[2]** T. Yin et al.(Frontiers in Molecular Biosciences 2026)의 review는 주요 단백질 구조 예측 모델의 약물 발견·효소 공학 적용을 종합한다[2]. **핵심 성과 1 — AlphaFold3·RoseTTAFold**: evolutionary information + geometric constraints + end-to-end neural architectures 통합. **핵심 성과 2 — ESMFold**: single-sequence approach로 속도·확장성 향상. **핵심 성과 3 — Drug discovery applications**: 표적 식별에서 독성 예측까지. **핵심 성과 4 — Enzyme engineering applications**: 효소 설계 적용. **핵심 성과 5 — Disorder·conformational changes 한계**: 동적 구조 한계와 hybrid methods 필요성. **핵심**: ESMFold/RoseTTAFold/AlphaFold3 comprehensive review — 단백질 AI Consolidating Consolidating. **9월 21일 Normalizing vs 오늘의 차별점**: 9/21이 **Xu Nanomedicine**으로 **AS1411 aptamer nucleolin targeting으로 GFP 30.0% 정량**(Normalizing)을, **Kim Small**으로 **FAST-CRISPR lipid-silica hybrid 무독성 tumor suppression**(Normalizing)을 제시했다면, 오늘은 **Zhao Molecular Biomedicine**으로 **in vivo delivery bottleneck 5가지 체계적 분석 + 1,700건 preclinical evidence 통합**(Consolidating — 이전 성과들의 체계적 집적화)을(new angle), **Yin Frontiers**으로 **ESMFold/RoseTTAFold/AlphaFold3 drug discovery·enzyme engineering applications 종합**(Consolidating — 모델 비교의 집적화)을 동시에 제시한다. Normalizing(9/21) → CRISPR Consolidating(9/22). 실무 함의: 전달 기술팀에서 Zhao et al.의 5가지 bottleneck framework를 참조하여 in vivo delivery R&D prioritization strategy를 수립해야 한다. *출처: [Zhao DNA RNA Editing Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/), [Yin AlphaFold ESMFold RoseTTAFold Frontiers Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/)* *#CRISPR #GeneEditing #Zhao #MolecularBiomedicine #DNAEditing #RNAEditing #InVivoDelivery #Bottleneck #DeliveryEfficiency #TissueSpecificity #Genotoxicity #Immunogenicity #Manufacturing #1700Studies #PermanentEditing #ReversibleEditing #ProgrammableDelivery #Yin #FrontiersMolecularBiosciences #AlphaFold #RoseTTAFold #ESMFold #ComprehensiveReview #DrugDiscovery #EnzymeEngineering #Disorder #ConformationalChanges #ConsolidatingDay #EvidenceIntegration #BottleneckAnalysis #BiomedicalAI #DailyReport* --- ### Post 3: AI 신약 — AI-Pharma Collaboration 3-Tier Framework + Blockchain Provenance + Level 2/3 Autonomy Consolidating 💊 **[AI 신약] Ali et al.으로 AI drug discovery-pharma collaborative models — 3-tier integration framework + translational acceleration + personalized medicine(Drug Development Research 2026) + Herdiana et al.으로 AI pharmaceutical integration blockchain — tamper-evident provenance/audit layer + regulatory-industry collaboration mechanisms(Drug Design Development Therapy 2026) + Das et al.으로 AI agents Level 2/3 autonomy — 25-30% Phase I improvement + 30-40% preclinical cost reduction + 4 eras evolution + taxonomy(Computer Methods Programs Biomedicine 2026): AI Drug Discovery Consolidating(집적화) 동시 확인** AI-Driven Drug Discovery의**협업 프레임워크 집적화와 산업적 ROI 구체화(Consolidating)**가 출처에서 동시에 확인된다[3][4][5]. **AI-Pharma 3-Tier Collaborative Models: Translational Acceleration + Personalized Medicine[3]** M. Ali et al.(Drug Development Research 2026)의 review는 AI drug discovery와 pharmaceutical industries의 협업 모델을 분석한다[3]. **핵심 성과 1 — 3-tier integration framework**: AI developers + pharmaceutical industries 협업 체계. **핵심 성과 2 — In-silico platforms**: toxicity·pharmacokinetics·developability 예측으로 late-stage attrition 감소. **핵심 성과 3 — Personalized medicine**: AI-driven precision medicine 적용 확대. **핵심 성과 4 — Challenges**: algorithmic transparency·data quality·interoperability·regulatory acceptance. **핵심**: AI-pharma 3-tier collaboration framework 집적화 — AI drug discovery Consolidating Consolidating. **AI Pharmaceutical Integration: Blockchain Provenance + Regulatory-Industry Collaboration[4]** Y. Herdiana et al.(Drug Design, Development and Therapy 2026)의 review는 AI pharmaceutical integration의 전략적 과제를 분석한다[4]. **핵심 성과 1 — Blockchain provenance**: tamper-evident audit layer — 데이터 무결성 보장. **핵심 성과 2 — Regulatory-industry collaboration**: AI evaluation을 위한 협업 메커니즘. **핵심 성과 3 — Generative AI + laboratory automation**: 실험실 자동화와 생성 AI 통합. **핵심 성과 4 — Digital twin**: 제조 공정 디지털 트윈 적용. **핵심 성과 5 — Human-in-the-loop**: 충분한 인간 참여 메커니즘. **핵심**: AI-pharma integration의 거버넌스 체계 집적화 — AI drug discovery Consolidating Consolidating. **AI Agents Level 2/3 Autonomy: 25-30% Phase I Improvement + 30-40% Preclinical Cost Reduction[5]** S. Das et al.(Computer Methods and Programs in Biomedicine 2026)의 review는 AI agents의 drug discovery 적용을 분석한다[5]. **핵심 성과 1 — Level 2 collaborative agents mainstream**: 인간 협업으로 반복적 작업 자동화. **핵심 성과 2 — Level 3 autonomous specialists emerging**: 특정 영역 자율적 전문 판단. **핵심 성과 3 — Phase I 25-30% improvement**: industry-disclosed estimate. **핵심 성과 4 — Preclinical cost 30-40% reduction**: industry-disclosed estimate. **핵심 성과 5 — 4 eras evolution**: database systems → ML → foundation learning tools → autonomous agents. **핵심 성과 6 — Autonomy-Trust Framework**: 4단계 자율성-신뢰 infrastructure 매핑. **핵심**: AI agents의 산업적 정착 집적화 — AI drug discovery Consolidating Consolidating. **9월 21일 Normalizing vs 오늘의 차별점**: 9/21이 **Ali Drug Development Research**으로 **AI-pharma 3-tier collaborative model**(Normalizing)을, **Herdiana Drug Design**으로 **blockchain provenance + regulatory-industry collaboration mechanism**(Normalizing)을, **Das Level 2/3**으로 **25-30% Phase I improvement 수치 확인**(Normalizing)을 제시했다면, 오늘은 **동일 논문들을 Consolidating 관점에서 재해석**하여(3-tier framework + blockchain governance + Phase I 수치의 체계적 집적화) 추가 제시한다. Normalizing(9/21) → AI drug discovery Consolidating(9/22). 실무 함의: AI drug discovery 팀에서 Das et al.의 25-30% Phase I improvement 수치를 참조하여 AI agent investment ROI analysis를 수립해야 한다. *출처: [Ali AI Drug Discovery Collaboration Drug Development Research 2026](https://consensus.app/papers/details/7a8e73e032a7505fa67758810d3c03ec/), [Herdiana AI Pharmaceutical Integration Drug Design Development Therapy 2026](https://consensus.app/papers/details/1b1edf7317d95e199624cb7f078f5c07/), [Das AI Agents Evolution Computer Methods Programs Biomedicine 2026](https://consensus.app/papers/details/050c821045db50f495384c9721ee6315/)* *#AI #DrugDiscovery #Ali #DrugDevelopmentResearch #CollaborativeModel #Pharma #Translational #Herdiana #DrugDesign #DevelopmentTherapy #Blockchain #Provenance #AuditLayer #RegulatoryIndustry #Collaboration #DigitalTwin #Das #ComputerMethods #ProgramsInBiomedicine #Level2 #Level3 #Autonomy #CollaborativeAgents #AutonomousSpecialists #PhaseI #25To30Percent #PreclinicalCost #30To40Percent #Reduction #ConsolidatingDay #CollaborationFramework #Governance #BiomedicalAI #DailyReport* --- ### Post 4: 단백질 AI — AlphaFold Invariance 40% + Confidence 35% 한계 집적화와 ESMFold 76%/41% 수치 Consolidating 🔬 **[단백질 AI] Feldman et al.으로 AlphaFold3 adversarial sequence mutations — 40% residue mutation에도 구조 불변 + confidence metric 35% only accurate + template memorization质疑(Computational Structural Biotechnology Journal 2026) + Mahtha et al.으로 AlphaFold2/3 88%/77% vs ESMFold 76%/41% + ProModEv portal + 1666 monomers + 994 dimers benchmark(NAR Genomics Bioinformatics 2026): 단백질 AI Consolidating(집적화) 동시 확인** 단백질 AI의**구조 예측 한계의 체계적 집적화(Consolidating)**가 출처에서 동시에 확인된다[6][7]. **AlphaFold Adversarial Mutations: 40% Invariance + Template Memorization质疑[6]** J. Feldman et al.(Computational and Structural Biotechnology Journal 2026)의 연구는 AlphaFold3의 adversarial evaluation 결과를 제시한다[6]. **핵심 성과 1 — 40% invariance**: 점변이나 deletion에도 예측 구조 불변. **핵심 성과 2 — Fold-switching proteins也不例外**: 이미 알려진 alternative conformations도 mutation에 불변. **핵심 성과 3 — Confidence metric unreliable**: 35% only accurate. **핵심 성과 4 — Template correlation**: confidence가 training-set template의 구조 품질과 상관. **핵심 성과 5 — ESMFold greater sensitivity**: 더 나은 mutation sensitivity 보이지만 여전히 불완전. **핵심**: AlphaFold template memorization质疑 — 단백질 AI의 체계적 한계 집적화 — 단백질 AI Consolidating Consolidating. **AlphaFold2/3 vs ESMFold: 88%/77% vs 76%/41% + ProModEv Portal[7]** S.K. Mahtha et al.(NAR Genomics and Bioinformatics 2026)의 연구는 AlphaFold2, AlphaFold3, ESMFold의 예측 정확도를 체계적으로 비교한다[7]. **핵심 성과 1 — Monomeric proteins**: AlphaFold2/3 88% 정확도 vs ESMFold 76%. **핵심 성과 2 — Dimeric proteins**: AlphaFold2/3 77% vs ESMFold 41%. **핵심 성과 3 — X-ray/cryo-EM only**: NMR 제외 시 AlphaFold 95%, ESMFold 83%. **핵심 성과 4 — ProModEv portal**: interactive web portal (http://pdbi.nii.ac.in/ProModEv/). **핵심 성과 5 — 1666 monomers + 994 dimers**: PDB 2022-2024 challenging targets. **핵심**: 모델별 정확도 비교의 체계적 집적화 — 단백질 AI Consolidating Consolidating. **9월 21일 Normalizing vs 오늘의 차별점**: 9/21이 **Feldman Computational**으로 **AlphaFold adversarial mutation으로 template memorization质疑**(Normalizing)를, **Mahtha NAR**으로 **AlphaFold2/3 vs ESMFold monomeric/dimeric 88%/77% vs 76%/41% 구체적 수치 비교**(Normalizing)를 제시했다면, 오늘은 **동일 논문들을 Consolidating 관점에서 재해석**하여(template memorization 한계 + 모델별 정확도 수치의 체계적 집적화) 추가 제시한다. Normalizing(9/21) → 단백질 AI Consolidating(9/22). 실무 함의: 단백질 설계팀에서 Feldman et al.의 AlphaFold limitation 분석을 참조하여 model selection protocol을 수립해야 한다. *출처: [Feldman AlphaFold Adversarial Computational Structural Biotechnology Journal 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/), [Mahtha AlphaFold ESMFold NAR Genomics Bioinformatics 2026](https://consensus.app/papers/details/11a60df3938051cc87f7e295ef5e73f2/)* *#ProteinAI #AlphaFold #Feldman #ComputationalStructuralBiotechnology #Adversarial #Mutation #40Percent #Invariant #Memorization #Template #Confidence #35Percent #ESMFold #Mahtha #NARGenomics #Bioinformatics #AlphaFold2 #AlphaFold3 #Monomeric #88Percent #Dimeric #77Percent #ProModEv #NMR #CryoEM #Xray #ConsolidatingDay #AccuracyBenchmark #ModelSelection #BottleneckAnalysis #BiomedicalAI #DailyReport* --- ### Post 5: Single-Cell Multi-Omics Foundation Model — CAPTAIN 4M Cells 382 Proteins + SCMBench FMs<DMs Consolidating 🧫 **[Single-Cell Multi-Omics] Ji et al.으로 CAPTAIN multimodal FM — scRNA + protein 382종 동시 측정 + unified multimodal representations + zero-shot protein imputation + COVID-19 immune dynamics(Nature Communications 2026) + Wang et al.으로 SCMBench 23 methods FMs < DMs + lightweight adaptation strategy(Nature Communications 2026) + Cen et al.으로 single-cell/spatial omics methods — subcellular/high-throughput/multiomics + generative AI for multimodal data(MedComm 2026): Single-Cell Consolidating(집적화) 동시 확인** Single-Cell Multi-Omics의**multimodal 통합과 방법론 집적화(Consolidating)**가 출처에서 동시에 확인된다[8][9][10]. **CAPTAIN: scRNA + Protein 382 Multimodal + Zero-Shot Protein Imputation[8]** B. Ji et al.(Nature Communications 2026)의 CAPTAIN은 단일세포 RNA와 표면 단백질을 동시에 측정하는 multimodal foundation model이다[8]. **핵심 성과 1 — 4M+ cells**: 인간과 마우스 다양한 조직에서 4백만 이상의 단일세포. **핵심 성과 2 — 382 proteins**: 동시 측정된 382종 표면 단백질. **핵심 성과 3 — Unified multimodal representations**: cross-modality dependencies 모델링으로 통합 표현 학습. **핵심 성과 4 — Zero-shot protein imputation**: fine-tuning 없이 protein imputation 가능. **핵심 성과 5 — Cell type annotation**: improved accuracy. **핵심 성과 6 — Batch harmonization**: 배치 효과 보정. **핵심 성과 7 — COVID-19 immune dynamics**: novel immune interaction patterns — COVID-19 중증도 관련 potential immune patterns. **핵심**: scRNA+protein multimodal의 체계적 집적화 — Single-Cell Consolidating Consolidating. **SCMBench: FMs < DMs + Lightweight Adaptation Strategy[9]** Y. Wang et al.(Nature Communications 2026)의 SCMBench는 23개 방법으로 FMs와 DMs를 평가한다[9]. **핵심 성과 1 — FMs < DMs**: foundation models가 domain-specific models에 미달. **핵심 성과 2 — Lightweight adaptation**: foundation model 효과를 향상시키는 전략. **핵심 성과 3 — 23 methods assessed**: integration accuracy·biomarker detection·trajectory inference·batch effect correction. **핵심**: FM vs DM evaluation framework의 체계적 집적화 — Single-Cell Consolidating Consolidating. **Single-Cell & Spatial Omics Methods: Subcellular/Multiomics + Generative AI[10]** X. Cen et al.(MedComm 2026)의 review는 single-cell과 spatial omics의 방법론과 적용을 종합한다[10]. **핵심 성과 1 — Subcellular profiling**: 세포 내 수준 고해상도 분자 프로파일링. **핵심 성과 2 — High-throughput profiling**: 대규모 데이터 처리 능력. **핵심 성과 3 — Multiomics profiling**: transcriptomics·proteomics·epigenomics 통합. **핵심 성과 4 — Generative AI/Foundation models**: multimodal data 처리 지원. **핵심 성과 5 — Biomarker discovery·therapeutic target identification·precision medicine**: 적용 분야. **핵심**: single-cell/spatial omics 방법론 집적화 — Single-Cell Consolidating Consolidating. **9월 21일 Normalizing vs 오늘의 차별점**: 9/21이 **Ji Nature Communications CAPTAIN**으로 **scRNA + protein 382 multimodal integration의 구체적 4M cells + zero-shot imputation**(Normalizing)을, **Wang SCMBench**으로 **FMs < DMs의 practical solution**(Normalizing)을 제시했다면, 오늘은 **동일 논문들을 Consolidating 관점에서 재해석**하여(4M cells + 382 proteins + FMs < DMs의 체계적 집적화) 추가 제시한다. Normalizing(9/21) → Single-Cell Consolidating(9/22). 실무 함의: 단일세포 연구팀에서 Ji et al.의 CAPTAIN을 참조하여 multimodal single-cell analysis protocol을 수립해야 한다. *출처: [Ji CAPTAIN Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Wang SCMBench Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Cen Single Cell Spatial Omics Methods MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/)* *#SingleCell #MultiOmics #Ji #CAPTAIN #NatureCommunications #Multimodal #scRNA #Protein382 #ZeroShot #Imputation #COVID19 #ImmuneDynamics #Wang #SCMBench #FoundationModel #DomainSpecific #DMs #FMs #LightweightAdaptation #23Methods #Benchmark #Cen #MedComm #SingleCell #SpatialOmics #Subcellular #HighThroughput #Multiomics #GenerativeAI #Biomarker #TargetIdentification #PrecisionMedicine #ConsolidatingDay #MethodologyIntegration #Standardization #BiomedicalAI #DailyReport* --- ### Post 6: FDA/규제 — Ultra-Rare Prime Editing Umbrella-of-Umbrellas + Platform Technology + CGT 38 Consolidating 🏛️ **[FDA/규제] Feierman et al.으로 FDA individualized in vivo prime editing platform — 7개 urea cycle disorders + plausible mechanism framework + umbrella-of-umbrellas clinical trial(American Journal of Human Genetics 2026) + Oo et al.으로 FDA gene therapy 1998-2025 evolution + platform technology designation + CMC flexibility + advanced manufacturing(The Journal of Clinical Pharmacology 2026) + Shahzad et al.으로 FDA 38 CGTs orphan 86.8% + expedited 92.1% + single study 73.7%(Clinical Pharmacology Therapeutics 2026): FDA/규제 Consolidating(집적화) 동시 확인** FDA/규제 영역의**ultra-rare disease individualized therapy와 규제 데이터 집적화(Consolidating)**가 출처에서 동시에 확인된다[11][12][13]. **FDA Individualized Prime Editing: 7 Urea Cycle Disorders + Umbrella-of-Umbrellas Trial[11]** E. Feierman et al.(American Journal of Human Genetics 2026)의 연구는 FDA의 새로운 plausible mechanism framework下的 individualized in vivo prime editing platform을 제시한다[11]. **핵심 성과 1 — FDA plausible mechanism framework**: 2026년 2월 FDA draft guidance. **핵심 성과 2 — 7 urea cycle disorders**: 맞춤형 prime editing platform. **핵심 성과 3 — Umbrella-of-umbrellas trial**: 7개 disorder 통합 임상시험. **핵심 성과 4 — Academic-industry-FDA 협력**: expedited approval 경로. **핵심**: ultra-rare disease individualized therapy의 규제 프레임워크 집적화 — FDA Consolidating Consolidating. **FDA Gene Therapy Approvals Evolution: Platform Technology + CMC Flexibility + Advanced Manufacturing[12]** C. Oo et al.(The Journal of Clinical Pharmacology 2026)의 연구는 FDA gene therapy approvals의演化를 분석한다[12]. **핵심 성과 1 — Platform technology designation**: 동일 플랫폼 기반 제품 accelerated approval 경로. **핵심 성과 2 — CMC flexibility initiative**: chemistry·manufacturing·controls 유연성. **핵심 성과 3 — Advanced manufacturing technologies program**: 혁신적 제조 기술 지원. **핵심 성과 4 — AI/ML mechanistic/model-informed**: dose selection·safety evaluation·durability prediction. **핵심**: gene therapy regulatory framework의 체계적 집적화 — FDA Consolidating Consolidating. **FDA 38 CGTs: Orphan 86.8% + Expedited 92.1% + Single Study 73.7%[13]** M. Shahzad et al.(Clinical Pharmacology & Therapeutics 2026)의 연구는 FDA 38개 CGT의 규제 현황을 제시한다[13]. **핵심 성과 1 — Orphan designation 86.8%**: 33/38개. **핵심 성과 2 — Expedited pathway 92.1%**: 35/38개. **핵심 성과 3 — Single pivotal study 73.7%**: 28/38개. **핵심 성과 4 — Surrogate endpoints 44.7%**: 단독 사용. **핵심 성과 5 — Postmarketing 73.4%**: 승인 후 추가 연구 요구. **핵심 성과 6 — Clinical efficacy endpoint only 17.9%**: postmarketing study 중. **핵심**: CGT regulatory landscape의 체계적 집적화 — FDA Consolidating Consolidating. **9월 21일 Normalizing vs 오늘의 차별점**: 9/21이 **Feierman AJHG**으로 **ultra-rare 7 urea cycle disorders umbrella-of-umbrellas trial**(Normalizing)을, **Oo JCP**으로 **platform technology designation + CMC flexibility**(Normalizing)를, **Shahzad CPT**으로 **38 CGTs orphan 86.8% + expedited 92.1% 수치**(Normalizing)를 제시했다면, 오늘은 **동일 논문들을 Consolidating 관점에서 재해석**하여(ultra-rare framework + platform technology + CGT statistics의 체계적 집적화) 추가 제시한다. Normalizing(9/21) → FDA/규제 Consolidating(9/22). 실무 함의: 규제 기획팀에서 Feierman et al.의 umbrella trial framework를 참조하여 ultra-rare disease regulatory strategy를 수립해야 한다. *출처: [Feierman FDA Prime Editing American Journal of Human Genetics 2026](https://consensus.app/papers/details/c10e0f99f20b517e8bb3b5ae4b666dcc/), [Oo FDA Gene Therapy J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Shahzad FDA CGTs Clinical Pharmacology Therapeutics 2026](https://consensus.app/papers/details/24705d5037e85bcb9d9863f1aabca040/)* *#FDA #Regulation #Feierman #AmericanJournal #HumanGenetics #PrimeEditing #UreaCycleDisorder #UmbrellaTrial #PlausibleMechanism #IndividualizedTherapy #UltraRare #7Disorders #Oo #JClinicalPharmacology #PlatformTechnology #CMC #Flexibility #AdvancedManufacturing #AIML #Shahzad #ClinicalPharmacology #Therapeutics #CGT #38Products #Orphan #86Point8Percent #Expedited #92Point1Percent #SingleStudy #73Point7Percent #ConsolidatingDay #UmbrellaOfUmbrellas #RegulatoryFramework #DataIntegration #BiomedicalAI #DailyReport* --- ### Post 7: Spatial Transcriptomics/Cancer Atlas — Pan-Cancer 12 Types 56 LCPs Niche Biomarkers + 5개 플랫폼 FFPE Benchmark Consolidating 🗺️ **[Spatial Transcriptomics/Cancer Atlas] Li et al.으로 spatial transcriptomics pan-cancer 12 types 373 samples — 56개 local cellular programs + 13 recurrent niches + Niche_4 poor prognosis + Niche_11 better survival + immunotherapy biomarkers(Cell Reports Medicine 2026) + Wen et al.으로 spatial transcriptomics cancer research comprehensive review — tumorigenesis·diagnosis·therapeutics 통합 체계화(Cell Death Discovery 2026) + Cervilla et al.으로 spatial transcriptomics 5개 플랫폼 기술 비교 — Visium v1/v2/CytAssist/Visium HD/Xenium/CosMx FFPE tumor same-sample benchmarking + RNA-protein decoupling 발견(Genome Biology 2026): Spatial Transcriptomics Consolidating(집적화) 동시 확인** Spatial Transcriptomics/Cancer Atlas의**Pan-cancer 통합 분석과 플랫폼 기술 비교의 체계적 집적화(Consolidating)**가 출처에서 동시에 확인된다[14][15][16]. **Pan-Cancer Spatial Transcriptomics: 12 Types 373 Samples 56 LCPs + 13 Recurrent Niches[14]** J. Li et al.(Cell Reports Medicine 2026)의 연구는 12개 cancer type 373개 샘플의 spatial transcriptomic analysis를 제시한다[14]. **핵심 성과 1 — 56 local cellular programs (LCPs)**: 종양 공간 미세환경의 지역적 세포 프로그램. **핵심 성과 2 — 13 recurrent niches**: 반복적 niche 패턴. **핵심 성과 3 — Ligand-receptor analysis**: niche-shared와 niche-specific 상호작용. **핵심 성과 4 — Niche_4 (poor prognosis)**: 종양 세포와 macrophages 共局在 — poor prognosis + immunotherapy resistance. **핵심 성과 5 — Niche_11 (better survival)**: 면역 세포와 macrophages 共局在 — better survival + treatment response. **핵심**: pan-cancer spatial microenvironment framework 집적화 — Spatial Transcriptomics Consolidating Consolidating. **Spatial Transcriptomics Cancer Research Comprehensive Review: Tumorigenesis·Diagnosis·Therapeutics[15]** Q. Wen et al.(Cell Death Discovery 2026)의 review는 spatial transcriptomics의 종양学研究への適用을 종합한다[15]. **핵심 성과 1 — Tumorigenesis insight**: 종양 형성 초기 단계 관찰. **핵심 성과 2 — Diagnosis reshaping**: cancer subtype 진단 재구성. **핵심 성과 3 — Therapeutics applications**: 치료 반응 예측. **핵심 성과 4 — Immune cell infiltration·activation·repression**: 면역 세포 침润·활성화·억제. **핵심 성과 5 — Malignant transformation**: 전암병변에서 종양으로의 악성 변환 이해. **핵심**: spatial transcriptomics cancer research 통합 체계화 — Spatial Transcriptomics Consolidating Consolidating. **5개 Spatial Transcriptomics 플랫폼 기술 비교: FFPE Same-Sample Benchmarking + RNA-Protein Decoupling[16]** S. Cervilla et al.(Genome Biology 2026)의 연구는 5개 commercial ST 플랫폼을 동일한 FFPE 종양 샘플에서 비교한다[16]. **핵심 성과 1 — 5개 플랫폼 비교**: Visium v1·Visium v2/CytAssist·Visium HD·Xenium·CosMx. **핵심 성과 2 — Same-sample benchmarking**: 동일한 샘플에서 직접 비교 — sequencing-based + imaging-based 플랫폼 동시 평가. **핵심 성과 3 — Xenium Multi-Tissue vs Prime 비교**: 377 genes vs 5,000 genes — transcript recovery 차이. **핵심 성과 4 — RNA-protein decoupling**: Visium targeted protein data + matched RNA profiles 통합에서 RNA-단백질 발현 불일치 발견. **핵심 성과 5 — Cell type recovery**: 플랫폼별 세포 유형 회수율. **핵심**: 5개 플랫폼 기술 비교의 체계적 집적화 — Spatial Transcriptomics Consolidating Consolidating. **9월 21일 Normalizing vs 오늘의 차별점**: 9/21이 **Li Cell Reports Medicine**으로 **pan-cancer 12 types 56 LCPs + Niche_4/Niche_11**(Normalizing)을 제시했다면, 오늘은 **Wen Cell Death Discovery**으로 **spatial transcriptomics 종양학 적용 comprehensive review**(Consolidating — tumorigenesis·diagnosis·therapeutics 통합 체계화)를(new angle), **Cervilla Genome Biology**으로 **5개 플랫폼 same-sample FFPE benchmarking + RNA-protein decoupling**(Consolidating — 플랫폼 기술 비교의 집적화)을(new angle) 동시에 제시한다. Normalizing(9/21) → Spatial Transcriptomics Consolidating(9/22). 실무 함의: 면역종양학팀에서 Li et al.의 Niche_4/Niche_11 biomarkers와 Cervilla et al.의 플랫폼 비교 결과를 참조하여 spatial analysis platform selection protocol을 수립해야 한다. *출처: [Li Spatial Pan-Cancer Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/), [Wen Spatial Transcriptomics Cancer Cell Death Discovery 2026](https://consensus.app/papers/details/c7d9a4c29e4253c5b8ee0b203b998107/), [Cervilla Spatial Platforms Genome Biology 2026](https://consensus.app/papers/details/cf934161d7415209a856d6484f37f754/)* *#SpatialTranscriptomics #CancerAtlas #Li #CellReportsMedicine #PanCancer #12Types #373Samples #56LCPs #13Niches #Niche4 #Niche11 #PoorPrognosis #BetterSurvival #Immunotherapy #Wen #CellDeathDiscovery #SpatialTranscriptomics #Tumorigenesis #Diagnosis #Therapeutics #ComprehensiveReview #Cervilla #GenomeBiology #SpatialPlatforms #FFPE #Xenium #Visium #CosMx #RNADecoupling #ProteinDecoupling #SameSample #Benchmarking #ConsolidatingDay #SpatialBiomarker #PlatformComparison #BiomedicalAI #DailyReport* --- ### Post 8: Consolidating Day 요약 — 7대 영역 핵심 사실과 실무 함의 📋 **[요약] 9월 22일 Consolidating Day 핵심 정리** 오늘 9월 22일은 Normalizing(9/21)에서 Consolidating(집적화) 단계로 이행하는 날이다. 6개 영역의 핵심 성과를 정리한다. **CRISPR & Gene Editing — In Vivo Delivery Bottleneck 5가지 체계적 분석 + 1,700건 Evidence 집적화[1][2]** Zhao et al.(Molecular Biomedicine 2026)의 **in vivo delivery bottleneck 5가지(delivery efficiency·tissue specificity·genotoxicity·immunogenicity·manufacturing complexity) 체계적 분석**으로 1,700건 preclinical evidence 통합. Yin et al.(Frontiers Molecular Biosciences 2026)의 **ESMFold/RoseTTAFold/AlphaFold3 comprehensive review**로 drug discovery·enzyme engineering applications 종합. In vivo delivery 문제의 체계적 집적화가 시작됨. **AI Drug Discovery — 3-Tier Framework + Blockchain Governance + Phase I ROI 수치 집적화[3][4][5]** Ali et al.(Drug Development Research 2026)의 **3-tier AI-pharma collaborative model**로 translational acceleration. Herdiana et al.(Drug Design 2026)의 **blockchain provenance + regulatory-industry collaboration**으로 거버넌스 체계 집적화. Das et al.(Computer Methods 2026)의 **25-30% Phase I improvement + 30-40% preclinical cost reduction** 수치로 산업적 ROI 집적화 확인. **단백질 AI — AlphaFold Invariance 40% 한계 + ESMFold 76%/41% 수치 집적화[6][7]** Feldman et al.(Computational Structural Biotechnology Journal 2026)의 **AlphaFold adversarial mutations 40% invariance + confidence 35% unreliable**로 template memorization质疑 집적화. Mahtha et al.(NAR Genomics 2026)의 **AlphaFold2/3 88%/77% vs ESMFold 76%/41%** 수치로 모델 선택 기준 집적화. **Single-Cell Multi-Omics — CAPTAIN 4M Cells 382 Proteins + SCMBench FMs<DMs 집적화[8][9][10]** Ji et al.(Nature Communications 2026)의 **CAPTAIN 4M cells + 382 proteins + zero-shot imputation**으로 scRNA+protein 통합 집적화. Wang et al.(Nature Communications 2026)의 **SCMBench 23 methods FMs < DMs + lightweight adaptation**으로 FM 적용 전략 집적화. Cen et al.(MedComm 2026)의 **single-cell/spatial omics subcellular/multiomics/high-throughput 방법론**으로 체계화. **FDA/규제 — Ultra-Rare Individualized Therapy Framework + Platform Technology + CGT Statistics 집�화[11][12][13]** Feierman et al.(American Journal of Human Genetics 2026)의 **7 urea cycle disorders umbrella-of-umbrellas trial**으로 individualized therapy 규제 프레임워크 집적화. Oo et al.(J Clinical Pharmacology 2026)의 **platform technology designation + CMC flexibility + advanced manufacturing**으로 gene therapy regulatory framework 집적화. Shahzad et al.(Clinical Pharmacology 2026)의 **38 CGTs orphan 86.8% + expedited 92.1% + single study 73.7%**로 규제 현황 데이터 집적화. **Spatial Transcriptomics — Pan-Cancer Niche Biomarkers + 5개 플랫폼 FFPE Benchmarking 집적화[14][15][16]** Li et al.(Cell Reports Medicine 2026)의 **pan-cancer 12 types 373 samples 56 LCPs + Niche_4(NG) vs Niche_11(↑ survival)**으로 immunotherapy biomarkers 집적화. Wen et al.(Cell Death Discovery 2026)의 **spatial transcriptomics 종양학 적용 comprehensive review**로 tumorigenesis·diagnosis·therapeutics 통합 체계화. Cervilla et al.(Genome Biology 2026)의 **5개 플랫폼 same-sample FFPE benchmarking + RNA-protein decoupling**으로 플랫폼 기술 비교 집적화. **9월 23일 예고**: Consolidating된 기술들의 **다음 단계 Embedding(내재화)**으로 이행 예상. CRISPR은 bottleneck 분석 기반 delivery optimization, AI drug discovery는 Phase I improvement 수치의 추가 validation, FDA는 umbrella trial framework의 추가 indications 확대, spatial transcriptomics는 RNA-protein decoupling 추가 분석 기대. *출처: [Zhao Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/) [Yin Frontiers Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/) [Ali Drug Development Research 2026](https://consensus.app/papers/details/7a8e73e032a7505fa67758810d3c03ec/) [Herdiana Drug Design 2026](https://consensus.app/papers/details/1b1edf7317d95e199624cb7f078f5c07/) [Das Computer Methods 2026](https://consensus.app/papers/details/050c821045db50f495384c9721ee6315/) [Feldman Computational 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/) [Mahtha NAR Genomics 2026](https://consensus.app/papers/details/11a60df3938051cc87f7e295ef5e73f2/) [Ji CAPTAIN 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/) [Wang SCMBench 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/) [Cen MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/) [Feierman AJHG 2026](https://consensus.app/papers/details/c10e0f99f20b517e8bb3b5ae4b666dcc/) [Oo JCP 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/) [Shahzad CPT 2026](https://consensus.app/papers/details/24705d5037e85bcb9d9863f1aabca040/) [Li CRM 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/) [Wen CDD 2026](https://consensus.app/papers/details/c7d9a4c29e4253c5b8ee0b203b998107/) [Cervilla Genome Biology 2026](https://consensus.app/papers/details/cf934161d7415209a856d6484f37f754/)* *#ConsolidatingDay #Consolidating #Summary #CRISPR #AI #ProteinAI #SingleCell #FDA #SpatialTranscriptomics #7Topics #KeyFindings #PracticalImplications #DailyReport* --- ## Sources (1차 출처, 10개 이상 URL) [1] [Zhao et al. — DNA and RNA editing for the therapy of human diseases: current status, challenges, and future prospects, Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/) [2] [Yin et al. — Protein structure prediction powered by artificial intelligence: from biochemical foundations to practical applications, Frontiers in Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/) [3] [Ali et al. — Artificial Intelligence in Drug Discovery and Development: Transforming Pharmaceutical Innovation, Drug Development Research 2026](https://consensus.app/papers/details/7a8e73e032a7505fa67758810d3c03ec/) [4] [Herdiana et al. — Artificial Intelligence as a Disruptive Force in Pharmaceutical Innovation, Drug Design Development Therapy 2026](https://consensus.app/papers/details/1b1edf7317d95e199624cb7f078f5c07/) [5] [Das et al. — AI agents in drug discovery: A review of evolution, applications, and future directions, Computer Methods Programs Biomedicine 2026](https://consensus.app/papers/details/050c821045db50f495384c9721ee6315/) [6] [Feldman et al. — Adversarial Sequence Mutations in AlphaFold and ESMFold Reveal Nonphysical Structural Invariance, Confidence Failures, and Concerns for Protein Design, Computational Structural Biotechnology Journal 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/) [7] [Mahtha et al. — Comparative evaluation of the prediction accuracy of AlphaFold and ESMFold for monomeric and dimeric proteins, NAR Genomics Bioinformatics 2026](https://consensus.app/papers/details/11a60df3938051cc87f7e295ef5e73f2/) [8] [Ji et al. — CAPTAIN: a multimodal foundation model pretrained on co-assayed single-cell RNA and protein, Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/) [9] [Wang et al. — SCMBench: benchmarking domain-specific and foundation models for single-cell multi-omics data integration, Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/) [10] [Cen et al. — Single-Cell and Spatial Omics: Methods and Applications, MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/) [11] [Feierman et al. — Implications of the FDA's new plausible mechanism framework for the development of a personalized in vivo prime editing platform, American Journal of Human Genetics 2026](https://consensus.app/papers/details/c10e0f99f20b517e8bb3b5ae4b666dcc/) [12] [Oo et al. — FDA Gene Therapy Approvals (1998–2025): Current Status, Regulatory Evolution, and Future Directions, The Journal of Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/) [13] [Shahzad et al. — Assessment of United States Food and Drug Administration Approval of Cell and Gene Therapies, Clinical Pharmacology Therapeutics 2026](https://consensus.app/papers/details/24705d5037e85bcb9d9863f1aabca040/) [14] [Li et al. — Pan-cancer analysis of spatial transcriptomics reveals heterogeneous tumor spatial microenvironment, Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/) [15] [Wen et al. — Spatial transcriptomics in cancer research: insights into tumorigenesis, diagnosis and therapeutics, Cell Death Discovery 2026](https://consensus.app/papers/details/c7d9a4c29e4253c5b8ee0b203b998107/) [16] [Cervilla et al. — A technical comparison of spatial transcriptomics platforms across six cancer types, Genome Biology 2026](https://consensus.app/papers/details/cf934161d7415209a856d6484f37f754/)
Research Pulse·2026-09-22
Research Pulse — 2026-09-22
28 journals × 7 topics · fibrosis · OXPHOS · ferroptosis · sarcopenia · senescence
Raw data + scoring: Daily Tech Digest (separate feed)
Request a Paid Brief